| Cat. No. |
Product Name |
Information |
| PC-63425 |
JNJ-47965567
P2X7 antagonist
|
JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively. |
| PC-63353 |
MK-3901
P2X3 antagonist
|
MK-3901 is a potent, selective, orally active P2X3 antagonist with IC50 of 21 nM. |
| PC-62763 |
JNJ-55308942
P2X7 antagonist
|
JNJ-55308942 is a highly potent, selective, brain-penetrant P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7. |
| PC-62755 |
RO-51
P2X3 antagonist
|
RO-51 is a potent, selective and drug-like dual P2X3 and P2X2/3 antagonist with pIC50 of 8.7 and 8.3, respectively. |
| PC-62754 |
AF-353
P2X3 antagonist
|
AF-353 (RO-4) is a potent, selective and drug-like dual P2X3 and P2X2/3 antagonist with pIC50 of 8.0 and 7.1, respectively. |
| PC-61827 |
AF-792
P2X3 antagonist
|
AF-792 (RO-5) is a potent, selective P2X3 and P2X2/3 antagonist with pIC50 of 8.2 and 7.9 respectively, with no inhibition at other P2X receptors. |
| PC-61622 |
JNJ-54175446
P2X7 antagonist
|
JNJ-54175446 is a potent and selective, brain penetrant P2X7 ion channel antagonist with pIC50 of 8.46 and 8.81 for hP2X7 and rP2X7, respectively. |
| PC-61575 |
CE-224535
P2X7 antagonist
|
CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP). |
| PC-61379 |
Gefapixant
P2X3 antagonist
|
Gefapixant (AF-219, MK-7264) is an orally active, small molecule antagonist of P2X3-containing receptor with IC50 of 30 nM (hP2X3 homotrimer) and 100-250 nM (hP2X2/3 heterotrimer). |
| PC-61123 |
JNJ 54166060
P2X7 antagonist
|
A potent, selective and orally bioavailable P2X7 receptor with IC50 of 4 nM and 115 nM for hP2X7 and rP2X7, respectively. |
| PC-60767 |
JNJ-42253432
P2X7 antagonist
|
JNJ-42253432 is a potent, selective, CNS-penetrant P2X7 antagonist with pKi of 9.1 and 7.9 for rat and huamn P2X7 channel, respectively. |
| PC-70094 |
AZD-9056
P2X7 antagonist
|
AZD-9056 is a potent, selective, orally bioavailable P2X7 receptor antagonist, inhibits release of pro-inflammatory mediators from isolated human peripheral monocytes (IL-1β and IL-18) and human alveolar macrophages (IL-1β) with IC50 values of 10-13 nM. |
